BioCentury | Mar 11, 2021
Deals

March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis

...new investors Tencent, Octagon Capital and New World Development Group’s Adrian Cheng and existing investors Nan Fung Life Sciences...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...Investments and returning investors Arch Venture Partners, Biomatics Capital, Decheng Capital, Tao Capital Partners and Nan Fung Life Sciences.Food...
BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...and Rakuten Medical Inc., as SVP of clinical development; Lazar Dimitrov, formerly investment director at Nan Fung Life Sciences...
BioCentury | Aug 29, 2020
Emerging Company Profile

Arctic Vision sets sights on China’s innovation gap in ophthalmology

...build some R&D in-house capabilities.” Arctic Vision launched in May 2019 after being incubated by Nan Fung Life Sciences...
...NoneCorporate partners: Clearside Biomedical Inc. (NASDAQ:CLSD), Eyenovia Inc. (NASDAQ:EYEN)Number of employees: About 20Funds raised: $32 millionInvestors: Nan Fung Life Sciences...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

...company closed a $6 million Series A-1 financing led by Khosla Ventures, with participation from Nan Fung Life Sciences...
...raised: $11 million Investors: Nan Fung Life Sciences, Khosla Ventures CEO: John Dimos Patents: None issued Danielle Golovin, Staff Writer Nan Fung Life Sciences Khosla...
BioCentury | Jul 2, 2020
Emerging Company Profile

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

...55 Funds raised: $170 million Investors: Novo Holdings, Vivo Capital, Pivotal bioVenture Partners, Sofinnova Investments, Nan Fung Life Sciences...
BioCentury | Jul 1, 2020
Emerging Company Profile

Engrail aims to build CNS pipeline by improving upon deprioritized assets

...preclinical or clinical proof of concept. “We know that CNS is a high risk area,” Nan Fung Life Sciences’...
...pursue unique indications based on the neural expression patterns of the receptor subtypes. Danielle Kopke, Staff Writer Nan Fung Life Sciences Novartis...
BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

...$6 million in a series A-1 financing led by new investor Khosla Ventures; existing investor Nan Fung Life Sciences...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...by Arch Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Sciences Ventures, Nan Fung Life Sciences...
BioCentury | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

...later-stage compounds with biomarkers, raised a tranched $80 million series B in June led by Nan Fung Life Sciences...
Items per page:
1 - 10 of 29
BioCentury | Mar 11, 2021
Deals

March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis

...new investors Tencent, Octagon Capital and New World Development Group’s Adrian Cheng and existing investors Nan Fung Life Sciences...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...Investments and returning investors Arch Venture Partners, Biomatics Capital, Decheng Capital, Tao Capital Partners and Nan Fung Life Sciences.Food...
BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...and Rakuten Medical Inc., as SVP of clinical development; Lazar Dimitrov, formerly investment director at Nan Fung Life Sciences...
BioCentury | Aug 29, 2020
Emerging Company Profile

Arctic Vision sets sights on China’s innovation gap in ophthalmology

...build some R&D in-house capabilities.” Arctic Vision launched in May 2019 after being incubated by Nan Fung Life Sciences...
...NoneCorporate partners: Clearside Biomedical Inc. (NASDAQ:CLSD), Eyenovia Inc. (NASDAQ:EYEN)Number of employees: About 20Funds raised: $32 millionInvestors: Nan Fung Life Sciences...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

...company closed a $6 million Series A-1 financing led by Khosla Ventures, with participation from Nan Fung Life Sciences...
...raised: $11 million Investors: Nan Fung Life Sciences, Khosla Ventures CEO: John Dimos Patents: None issued Danielle Golovin, Staff Writer Nan Fung Life Sciences Khosla...
BioCentury | Jul 2, 2020
Emerging Company Profile

Bolt’s myeloid twist on ADCs charged up with $93.5M series C

...55 Funds raised: $170 million Investors: Novo Holdings, Vivo Capital, Pivotal bioVenture Partners, Sofinnova Investments, Nan Fung Life Sciences...
BioCentury | Jul 1, 2020
Emerging Company Profile

Engrail aims to build CNS pipeline by improving upon deprioritized assets

...preclinical or clinical proof of concept. “We know that CNS is a high risk area,” Nan Fung Life Sciences’...
...pursue unique indications based on the neural expression patterns of the receptor subtypes. Danielle Kopke, Staff Writer Nan Fung Life Sciences Novartis...
BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

...$6 million in a series A-1 financing led by new investor Khosla Ventures; existing investor Nan Fung Life Sciences...
BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

...by Arch Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Sciences Ventures, Nan Fung Life Sciences...
BioCentury | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

...later-stage compounds with biomarkers, raised a tranched $80 million series B in June led by Nan Fung Life Sciences...
Items per page:
1 - 10 of 29